Eli Lilly and Company $LLY Shares Sold by SMART Wealth LLC

SMART Wealth LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 65.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 920 shares of the company’s stock after selling 1,764 shares during the period. SMART Wealth LLC’s holdings in Eli Lilly and Company were worth $1,103,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC lifted its stake in shares of Eli Lilly and Company by 14.7% during the second quarter. Retirement Wealth Solutions LLC now owns 109 shares of the company’s stock worth $131,000 after purchasing an additional 14 shares in the last quarter. Legacy Wealth Managment LLC ID boosted its holdings in shares of Eli Lilly and Company by 297.3% in the 2nd quarter. Legacy Wealth Managment LLC ID now owns 445 shares of the company’s stock valued at $533,000 after buying an additional 333 shares during the period. LifePlan Investment Advisors Inc. raised its position in shares of Eli Lilly and Company by 8.6% during the 2nd quarter. LifePlan Investment Advisors Inc. now owns 405 shares of the company’s stock worth $485,000 after purchasing an additional 32 shares during the period. NWF Advisory Services Inc. lifted its position in Eli Lilly and Company by 8.0% in the 2nd quarter. NWF Advisory Services Inc. now owns 2,136 shares of the company’s stock valued at $2,562,000 after purchasing an additional 159 shares during the last quarter. Finally, Syon Capital LLC raised its stake in Eli Lilly and Company by 2.5% during the 2nd quarter. Syon Capital LLC now owns 13,135 shares of the company’s stock valued at $15,755,000 after acquiring an additional 316 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large obesity-drug opportunity: J.P. Morgan estimates Eli Lilly could benefit from a roughly $100 billion incretin opportunity. Zepbound and Mounjaro continue to provide substantial growth, while next-generation therapies could extend the company’s expansion beyond its current products. Eli Lilly’s $100B incretin opportunity: Is more upside coming?
• Positive Sentiment: Acquisitions could diversify future growth: Recent deals are being viewed as an effort to build Eli Lilly’s long-term pipeline and reduce reliance on today’s blockbuster GLP-1 medicines. The strategy could support additional revenue streams as the company’s core drugs mature. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
• Positive Sentiment: Institutional buying signals confidence: Citadel Advisors and Duquesne Family Office reportedly purchased LLY shares during the second quarter, potentially viewing an earlier pullback as an attractive entry point. Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
• Neutral Sentiment: Analyst and Zacks comparisons portray Lilly as the higher-growth choice versus Johnson & Johnson, but also note that investors must accept greater product-concentration and execution risks. Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
• Negative Sentiment: Competition and patent limits remain key overhangs: Mounjaro, Zepbound and other leading products face increasing competition, while their patent protection is time-limited. Those concerns may be contributing to caution after the stock’s strong run, particularly given its premium earnings multiple. Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Jefferies Financial Group upped their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. BMO Capital Markets upgraded shares of Eli Lilly and Company from an “outperform” rating to a “buy” rating in a research note on Tuesday, September 1st. Finally, Sanford C. Bernstein lifted their price target on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,292.18.

Insider Buying and Selling

In other news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,147.06 on Tuesday. Eli Lilly and Company has a one year low of $712.05 and a one year high of $1,292.65. The firm has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 38.49, a PEG ratio of 1.42 and a beta of 0.50. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The business has a fifty day simple moving average of $1,190.13 and a 200 day simple moving average of $1,070.66.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts expect that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 23.22%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.